DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1ALPHA,25-DIHYDROXYVITAMIN D3
Compounds of formula I are provided where X 1 , X 2 , and X 3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.
1 . A compound having the formula I
wherein X 1 , X 2 , and X 3 are independently selected from H and hydroxy protecting groups.
2 . The compound of claim 1 , wherein X 1 , X 2 , and X 3 are hydroxy protecting groups.
3 . The compound of claim 2 , wherein X 1 and X 2 are both t-butyldimethylsilyl groups and X 3 is a triethylsilyl group.
4 . A compound having the formula II
5 . The compound of claim 4 , having the formula IIA
6 . The compound of claim 4 , having the formula IIB
7 . The compound of claim 4 , having the formula IIC
8 . The compound of claim 4 , having the formula IID
9 . The compound of claim 4 , having the formula IIE, IIF, IIG, or IIH
10 . A pharmaceutical composition, comprising an effective amount of the compound of claim 4 and a pharmaceutically acceptable carrier.
11 . The pharmaceutical composition of claim 10 wherein the effective amount comprises from about 0.01 μg to about 1 mg of the compound per gram of the composition,
12 . The pharmaceutical composition of claim 10 wherein the effective amount comprises from about 0.1 μg to about 500 μg of the compound per gram of the composition.
13 . A method of treating a subject suffering from a biological condition, comprising administering an effective amount of the compound of claim 4 to the subject, wherein the biological condition is selected from psoriasis; leukemia; colon cancer; breast cancer; prostate cancer; multiple sclerosis; lupus; diabetes mellitus; host versus graft, reaction; rejection of organ transplants; an inflammatory disease selected from rheumatoid arthritis, asthma, or inflammatory bowel diseases; a skin condition selected from wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration, or insufficient sebum secretion; renal osteodystrophy; or osteoporosis.
14 . The method of claim 13 , wherein the biological condition is psoriasis.
15 . The method of claim 13 , wherein the biological condition is selected from leukemia, colon cancer, breast cancer, or prostate cancer.
16 . The method of claim 13 , wherein the biological condition is selected from multiple sclerosis, lupus, diabetes mellitus host versus grail reaction, or rejection of organ transplants.
17 . The method of claim 13 , wherein the biological condition is selected from rheumatoid arthritis, asthma, or inflammatory bowel diseases selected from celiac disease, ulcerative colitis and Crohn's disease.
18 . The method of claim 13 , wherein the biological condition is selected from wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration, or insufficient sebum secretion.
19 . The method of claim 13 , wherein the compound is administered orally, parenterally, transdermally, or topically to the subject.
20 . The method of claim 13 , wherein the compound is administered in a dosage of from 0.01 μg per day to 1 mg per day.